Sagebrush Inn & Suites Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics (A2)
Organizer(s) Gary D. Wu, Scott Snapper, Judy H. Cho and Aida Habtezion
January 13—17, 2019
Sagebrush Inn & Suites • Taos, New Mexico USA
Discounted Abstract Deadline: Oct 4, 2018
Abstract Deadline: Oct 16, 2018
Scholarship Deadline: Oct 4, 2018
Discounted Registration Deadline: Nov 13, 2018
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Takeda Pharmaceutical Company Limited and Theravance Biopharma
Summary of Meeting:
Inflammatory bowel diseases (IBD), which afflict millions of patients, are rapidly increasing in incidence world-wide in parallel with industrialization. Pathogenesis involves both host genetic as well environmental factors, with the most currently utilized therapeutics focusing on long-term host immunosuppression. Despite tremendous advances in our understanding of IBD genetics, the mucosal immune system, and environmental factors such as the gut microbiome, currently available therapeutic modalities for IBD remain suboptimal. The overall goal of this conference is to bring together world-class investigators and clinicians to discuss the latest scientific knowledge relevant to the pathogenesis of IBD and facilitate an interactive discussion to accelerate development of new opportunities to prevent and/or treat IBD. The specific aims of this conference are to: 1) Bring together a combination of clinical and basic investigators from both academia and industry to facilitate cross-disciplinary discussions focused on IBD; 2) Identify both opportunities and gaps in current knowledge of the pathogenesis of IBD important for the development of new diagnostics and therapeutics; and 3) Create a multidisciplinary environment that will inspire both young and established investigators by highlighting currently available opportunities in IBD research. The anticipated outcome will be a better understanding of the advances and challenges in developing new therapies for patients with IBD.
View Scholarships/Awards
Inflammatory bowel diseases (IBD), which afflict millions of patients, are rapidly increasing in incidence world-wide in parallel with industrialization. Pathogenesis involves both host genetic as well environmental factors, with the most currently utilized therapeutics focusing on long-term host immunosuppression. Despite tremendous advances in our understanding of IBD genetics, the mucosal immune system, and environmental factors such as the gut microbiome, currently available therapeutic modalities for IBD remain suboptimal. The overall goal of this conference is to bring together world-class investigators and clinicians to discuss the latest scientific knowledge relevant to the pathogenesis of IBD and facilitate an interactive discussion to accelerate development of new opportunities to prevent and/or treat IBD. The specific aims of this conference are to: 1) Bring together a combination of clinical and basic investigators from both academia and industry to facilitate cross-disciplinary discussions focused on IBD; 2) Identify both opportunities and gaps in current knowledge of the pathogenesis of IBD important for the development of new diagnostics and therapeutics; and 3) Create a multidisciplinary environment that will inspire both young and established investigators by highlighting currently available opportunities in IBD research. The anticipated outcome will be a better understanding of the advances and challenges in developing new therapies for patients with IBD.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, January 13 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 17 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 18 in order to fully experience the meeting.
SUNDAY, JANUARY 13
MONDAY, JANUARY 14
TUESDAY, JANUARY 15
WEDNESDAY, JANUARY 16
THURSDAY, JANUARY 17
FRIDAY, JANUARY 18
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, January 13 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 17 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 18 in order to fully experience the meeting.
SUNDAY, JANUARY 13
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Gary D. Wu,
Perelman School of Medicine, University of Pennsylvania, USA
Fiona M. Powrie,
University of Oxford, UK
Gut Reactions: Immune Pathways in the Intestine in Health and Disease
Gut Reactions: Immune Pathways in the Intestine in Health and Disease
09:00—11:30
Clinical Considerations of IBD—What’s the Goal?
Meeting has ended...abstracts no longer viewable online.
*
Gary D. Wu,
Perelman School of Medicine, University of Pennsylvania, USA
Gilaad Kaplan,
University of Calgary, Canada
Clinical Epidemiology: The Rising Incidence of IBD Associated with Industrialization
Clinical Epidemiology: The Rising Incidence of IBD Associated with Industrialization
Coffee Break
Dermot P. B. McGovern,
Cedars Sinai Medical Center, USA
Using Genomics to Explain the Clinical Heterogeneity of IBD
Using Genomics to Explain the Clinical Heterogeneity of IBD
Séverine Vermeire,
KU Leuven, Belgium
Current and Future Therapeutics with Companion Diagnostics in IBD
Current and Future Therapeutics with Companion Diagnostics in IBD
John Y. Kao,
University of Michigan, USA
Short Talk: Congenital Hypothyroidism Is a Risk Factor for Inflammatory Bowel Disease
Short Talk: Congenital Hypothyroidism Is a Risk Factor for Inflammatory Bowel Disease
Angela Mo,
Georgia Institute of Technology, USA
Short Talk: An Expression Based Risk Score for Prediction of Disease Course in Pediatric Ulcerative Colitis
Short Talk: An Expression Based Risk Score for Prediction of Disease Course in Pediatric Ulcerative Colitis
14:30—16:30
Workshop 1: Host Factors in IBD
*
Scott Snapper,
Boston Children’s Hospital, USA
*
Aida Habtezion,
Stanford School of Medicine, USA
June-Yong Lee,
New York University School of Medicine, USA
Pathogenic Role of Serum Amyloid A Proteins in Th17-Mediated Chronic Inflammation
Pathogenic Role of Serum Amyloid A Proteins in Th17-Mediated Chronic Inflammation
Phi Luong,
Boston Children's Hospital, USA
C1ORF106/INAVA-ARNO Complexes Bridge Mucosal Barrier Function with Inflammatory Signaling
C1ORF106/INAVA-ARNO Complexes Bridge Mucosal Barrier Function with Inflammatory Signaling
Kairui Mao,
NIAID, National Institutes of Health, USA
Sequential Innate and Adaptive Immunity Establishes Non-Inflammatory Gut Commensalism and Physiologic Host Lipid Metabolism
Sequential Innate and Adaptive Immunity Establishes Non-Inflammatory Gut Commensalism and Physiologic Host Lipid Metabolism
Vu Ngo,
Georgia State University, USA
IL-36 Receptor Signaling Orchestrates IL-23-Mediated Gut Barrier Repair and Defense
IL-36 Receptor Signaling Orchestrates IL-23-Mediated Gut Barrier Repair and Defense
Samuel Rubin,
Stanford University School of Medicine, USA
Mass Cytometry Reveals Systemic and Local Immune Signatures that Distinguish Inflammatory Bowel Diseases
Mass Cytometry Reveals Systemic and Local Immune Signatures that Distinguish Inflammatory Bowel Diseases
17:00—19:00
Advances in the Genetics of IBD
Meeting has ended...abstracts no longer viewable online.
*
Carl Anderson,
Sanger Institute, UK
Judy H. Cho,
Icahn School of Medicine at Mount Sinai, USA
Precision IBD and Population Differences in Innate Immunity
Precision IBD and Population Differences in Innate Immunity
Ramnik Xavier,
Massachusetts General Hospital, USA
From IBD-Associated Genotypes to Altered Cellular and Organismal Function
From IBD-Associated Genotypes to Altered Cellular and Organismal Function
Olga Sazonova,
23andMe, USA
Short Talk: Polygenic Modeling Identifies Individuals whose Genetic Risk for IBD Is Comparable to Positive Family History
Short Talk: Polygenic Modeling Identifies Individuals whose Genetic Risk for IBD Is Comparable to Positive Family History
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
The Mucosal Immune System in IBD—Innate Immunity
Meeting has ended...abstracts no longer viewable online.
*
Aida Habtezion,
Stanford School of Medicine, USA
Richard S. Blumberg,
Brigham and Women's Hospital, USA
FcRn Defines Immune Responses to IgG-Containing Immune Complexes
FcRn Defines Immune Responses to IgG-Containing Immune Complexes
Clara Abraham,
Yale University, USA
Modulation of Innate Immune Responses by IBD-associated Genes
Modulation of Innate Immune Responses by IBD-associated Genes
Coffee Break
Gérard Eberl,
Institut Pasteur, France
Type 3 Innate Lymphoid Cells Facing Dietary and Microbial Perturbations
Type 3 Innate Lymphoid Cells Facing Dietary and Microbial Perturbations
Gabriel Nuñez,
University of Michigan, USA
Specific NOD2-Microbiota Interactions Drive Crohn's-Like Disease
Specific NOD2-Microbiota Interactions Drive Crohn's-Like Disease
Randy S. Longman,
Weill Cornell Medical College, USA
Short Talk: Intestinal Mononuclear Phagocyte-Derived TL1A Is a Central Regulator of Group 3 Innate Lymphoid Cells in Inflammatory Bowel Disease
Short Talk: Intestinal Mononuclear Phagocyte-Derived TL1A Is a Central Regulator of Group 3 Innate Lymphoid Cells in Inflammatory Bowel Disease
William McAlpine,
University of Texas Southwestern, USA
Short Talk: Loss of SMCR8 or WDR41 Results in Immune Dysregulation and Colitis Susceptibility
Short Talk: Loss of SMCR8 or WDR41 Results in Immune Dysregulation and Colitis Susceptibility
Naresh Singh Redhu,
Boston Children's Hospital, USA
Short Talk: Deletion of STAT1 Ameliorates Early-Onset Colitis in IL10R-deficient Mice
Short Talk: Deletion of STAT1 Ameliorates Early-Onset Colitis in IL10R-deficient Mice
17:00—19:00
The Mucosal Immune System in IBD—Adaptive Immunity
Meeting has ended...abstracts no longer viewable online.
*
Scott Snapper,
Boston Children’s Hospital, USA
Eoin McKinney,
Cambridge University, UK
T-Cell Exhaustion, Co-Stimulation and Clinical Outcome in Autoimmunity and Infection
T-Cell Exhaustion, Co-Stimulation and Clinical Outcome in Autoimmunity and Infection
Vijay K. Kuchroo,
Brigham and Women's Hospital, Harvard Medical School, USA
Induction of Effector and Regulatory T Cells
Induction of Effector and Regulatory T Cells
Aida Habtezion,
Stanford School of Medicine, USA
Trafficking and Immune Response in IBD
Trafficking and Immune Response in IBD
Wei Yang,
University of Alabama at Birmingham, USA
Short Talk: Protein Kinase 2 (CK2) Is Required for CD4+ T Cell Function in the Pathogenesis of Colitis
Short Talk: Protein Kinase 2 (CK2) Is Required for CD4+ T Cell Function in the Pathogenesis of Colitis
Yu Hui Kang,
Boston Children's Hospital, USA
Short Talk: STAT1 Signaling Shields T Cells from NK Cell-Mediated Cytotoxicity to Enable Intestinal Inflammation
Short Talk: STAT1 Signaling Shields T Cells from NK Cell-Mediated Cytotoxicity to Enable Intestinal Inflammation
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
The Environment in IBD Pathogenesis (Microbiome)
Meeting has ended...abstracts no longer viewable online.
*
June L. Round,
University of Utah, USA
A Role for Fungi in IBD
A Role for Fungi in IBD
Coffee Break
Andrew J.S. Macpherson,
University of Bern, Switzerland
Microbial Network Disturbances in Relapsing Refractory Crohn’s Disease
Microbial Network Disturbances in Relapsing Refractory Crohn’s Disease
David N. Cook,
Seres Therapeutics, Inc., USA
A Novel Approach to Treating Active Ulcerative Colitis using Microbial Consortia
A Novel Approach to Treating Active Ulcerative Colitis using Microbial Consortia
Samantha Hsieh,
Washington University School of Medicine, USA
Short Talk: Diet Modulates T Cell Immune Responses by Regulating the Expression of a Dominant Antigen from a Gut Symbiont
Short Talk: Diet Modulates T Cell Immune Responses by Regulating the Expression of a Dominant Antigen from a Gut Symbiont
Eric C. Martens,
University of Michigan Medical School, USA
Short Talk: Combined Low Dietary Fiber and Mucus-Degrading Symbiotic Gut Bacteria Cause Lethal Colitis in IL-10 Deficient Mice
Short Talk: Combined Low Dietary Fiber and Mucus-Degrading Symbiotic Gut Bacteria Cause Lethal Colitis in IL-10 Deficient Mice
Amira Metwaly,
Technical University of Munich, Germany
Short Talk: Integrative Multi-Omics Identification of Biomarker Microbial Signatures
Short Talk: Integrative Multi-Omics Identification of Biomarker Microbial Signatures
14:30—16:30
Workshop 2: Environmental Factors in IBD
*
Judy H. Cho,
Icahn School of Medicine at Mount Sinai, USA
*
Gary D. Wu,
Perelman School of Medicine, University of Pennsylvania, USA
Roberta Caruso,
University of Michigan, USA
Specific Host-Microbiota Interactions Drive the Development of Crohn’s Disease-Like Colitis in Mice
Specific Host-Microbiota Interactions Drive the Development of Crohn’s Disease-Like Colitis in Mice
Benoit Chassaing,
Georgia State University, USA
Dietary Emulsifiers Directly Impact Adherent and Invasive E. coli, Promoting Intestinal Inflammation
Dietary Emulsifiers Directly Impact Adherent and Invasive E. coli, Promoting Intestinal Inflammation
Uri Gophna,
Tel Aviv University, Israel
Prolonged Antibiotic Treatment of Pouchitis Generates Broad Microbiome-Wide Resistance to Fluoroquinolones as well as Collateral Resistance
Prolonged Antibiotic Treatment of Pouchitis Generates Broad Microbiome-Wide Resistance to Fluoroquinolones as well as Collateral Resistance
Nobuhiko Kamada,
University of Michigan, USA
Adherent-Invasive Escherichia coli Employs Diet-Derived Amino Acids to Maximize its Fitness in the Inflamed Gut
Adherent-Invasive Escherichia coli Employs Diet-Derived Amino Acids to Maximize its Fitness in the Inflamed Gut
Serre-Yu Wong,
Mount Sinai Hospital, USA
Host Microbe and Intra-Microbiome Interactions Leading to Small Intestinal Inflammation in Nod2-/- Mice
Host Microbe and Intra-Microbiome Interactions Leading to Small Intestinal Inflammation in Nod2-/- Mice
Sungwhan F. Oh,
Brigham and Women's Hospital/Harvard Medical School, USA
Structure and Immunoprotective Functions of Gut Symbiotic Glycosphingolipids: Direct Impact of the Host Diet
Structure and Immunoprotective Functions of Gut Symbiotic Glycosphingolipids: Direct Impact of the Host Diet
Hao Tran,
Georgia State University, USA
Flagellin-Elicited Adaptive Immunity Suppresses Flagellated Microbiota and Vaccinates against Chronic Inflammatory Diseases
Flagellin-Elicited Adaptive Immunity Suppresses Flagellated Microbiota and Vaccinates against Chronic Inflammatory Diseases
Emilie Viennois,
Georgia State University, USA
Fecal miRNAs, Mediators of the Host-Microbiota Interaction, Can Restore Intestinal Health
Fecal miRNAs, Mediators of the Host-Microbiota Interaction, Can Restore Intestinal Health
17:00—19:00
Barrier Function in IBD
Meeting has ended...abstracts no longer viewable online.
*
Dirk Haller,
Technical University of Munich, Germany
Thaddeus S. Stappenbeck,
Washington University School of Medicine, USA
The Intestinal Epithelium in IBD
The Intestinal Epithelium in IBD
Lora V. Hooper,
University of Texas Southwestern Medical Center, USA
Interactions among the Microbiota, the Immune System and the Circadian Clock
Interactions among the Microbiota, the Immune System and the Circadian Clock
Andrew T. Gewirtz,
Georgia State University, USA
Gut microbiota, Diet and Chronic Inflammation
Gut microbiota, Diet and Chronic Inflammation
Pradipta Ghosh,
University of California, San Diego, USA
Short Talk: Network-Based Approaches to Improve Precision and Prediction in IBD Therapeutics
Short Talk: Network-Based Approaches to Improve Precision and Prediction in IBD Therapeutics
Jordi M. Lanis,
University of Colorado Anschutz Medical Campus, USA
Short Talk: Contributions of Creatine Kinase to Mucosal Immune Responses in Murine Colitis
Short Talk: Contributions of Creatine Kinase to Mucosal Immune Responses in Murine Colitis
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Translational Opportunities (Bench to Bedside and Back Again)
Meeting has ended...abstracts no longer viewable online.
*
Judy H. Cho,
Icahn School of Medicine at Mount Sinai, USA
Gary D. Wu,
Perelman School of Medicine, University of Pennsylvania, USA
Engineering the Gut Microbiome in IBD
Engineering the Gut Microbiome in IBD
Scott Snapper,
Boston Children’s Hospital, USA
Identifying Novel Immune Therapeutics through Studying Rare Diseases
Identifying Novel Immune Therapeutics through Studying Rare Diseases
Coffee Break
Gregory C. Gibson,
Georgia Institute of Technology, USA
Integrative Genomics in Discriminating IBD Progression
Integrative Genomics in Discriminating IBD Progression
Markus F. Neurath,
University Hospital Erlangen, Germany
Bridging the Gap between IBD Pathogenesis and the Development of New Therapeutics
Bridging the Gap between IBD Pathogenesis and the Development of New Therapeutics
Dominic Boardman,
University of British Columbia, Canada
Short Talk: Engineering Flagellin-Specific Regulatory T Cells to Restore Intestinal Homeostasis in IBD
Short Talk: Engineering Flagellin-Specific Regulatory T Cells to Restore Intestinal Homeostasis in IBD
Ting Fu,
The Salk Institute, USA
Short Talk: Nutritional Modulation of Intestinal Innate Immunity by BA-FXR Axis
Short Talk: Nutritional Modulation of Intestinal Innate Immunity by BA-FXR Axis
17:00—18:45
New Technologies and Collaborations between Industry and Academia
Meeting has ended...abstracts no longer viewable online.
*
Clara Abraham,
Yale University, USA
Scott Plevy,
Janssen, USA
Restoration of Immune and Microbial Homeostasis by a Live Bacterial Therapeutic: Investigations into Mechanisms and Development of VE202
Restoration of Immune and Microbial Homeostasis by a Live Bacterial Therapeutic: Investigations into Mechanisms and Development of VE202
Chas Bountra,
University of Oxford, UK
Big Data in Pharma-Academic Collaborations
Big Data in Pharma-Academic Collaborations
Elizabeth Wiellette,
Draper Laboratory, USA
Short Talk: A High-Throughput Microphysiologic System to Accurately Model Human Colon and Ileum
Short Talk: A High-Throughput Microphysiologic System to Accurately Model Human Colon and Ileum
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
